Long-term safety of dapirolizumab pegol in people with lupus
Tests dapirolizumab pegol's long-term safety in people with systemic lupus erythematosus.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Key facts
- Where
- Beijing, Changchun, Guangzhou, Guilin, Shanghai, Shantou, Suzhou, Tianjin, Wenzhou, Wuhan, Yangzhou, and Zhengzhou, ChinaSee the 12 sites
- Phase
- Phase 3
Where in China
- Sl0046 20128Beijing, ChinaNo longer taking part
- Sl0046 20291Changchun, ChinaNo longer taking part
- Sl0046 20019Guangzhou, ChinaNo longer taking part
- Sl0046 20290Guilin, ChinaNo longer taking part
- Sl0046 20020Shanghai, ChinaNo longer taking part
- Sl0046 20346Shantou, ChinaNo longer taking part
- Sl0046 20204Suzhou, ChinaNo longer taking part
- Sl0046 20136Tianjin, ChinaNo longer taking part
- Sl0046 20025Wenzhou, ChinaNo longer taking part
- Sl0046 20180Wuhan, ChinaNo longer taking part
- Sl0046 20273Yangzhou, ChinaNo longer taking part
- Sl0046 20132Zhengzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UCB Biopharma SRL
- Trial code
- NCT04976322EU 2023-506368-14-00
- Record updated
- 15 October 2026
- Original description
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.Read full original descriptionShow less
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.
Inclusion: The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment; The participant completed one of the parent studies within 4 weeks prior to entry to this study.
Exclusion: Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study.